Infectious diseases
16 public biotech companies we cover are developing treatments for hepatitis B and D, COVID-19, influenza, RSV, bacterial infections and vaccines. 8 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- Arbutus Biopharma (ABUS)Thesis Challenged
Chronic hepatitis B
- Arrowhead Pharmaceuticals (ARWR)Thesis Intact
Chronic hepatitis b
- Assembly Biosciences (ASMB)Thesis Intact
Herpesvirus infection, Recurrent genital herpes, Hepatitis b virus infection, Chronic hepatitis delta virus, and 2 more
- Capricor Therapeutics (CAPR)Thesis Broken
Vaccine, COVID-19
- Evaxion (EVAX)Thesis Intact
Cytomegalovirus, Group A Streptococcus, Cytomegalovirus infection
- Immunocore (IMCR)Thesis Intact
Chronic hepatitis b, Human immunodeficiency virus infection
- Invivyd (IVVD)Thesis Challenged
Measles, COVID-19, Long covid, RSV prophylaxis, and 2 more
- Ionis Pharmaceuticals (IONS)Thesis Intact
Chronic hepatitis b
- Ocugen (OCGN)Thesis Intact
COVID-19
- PolyPid (PYPD)Thesis Intact
Surgical site infection, Surgical site infection prevention
- Precision BioSciences (DTIL)Thesis Intact
Hepatitis b, Chronic Hepatitis B
- Soligenix (SNGX)Thesis Broken
COVID-19, Ebola virus disease, Marburg virus disease, Antibiotic-resistant infection
- Tiziana Life Sciences (TLSA)Thesis Challenged
Long covid
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Mpox, Smallpox, Lyme disease, Viral infections, and 2 more
- Traws Pharma (TRAW)Thesis Challenged
Bird flu, COVID-19, Influenza, Acute infection, and 3 more
- Vaxcyte (PCVX)Thesis Intact
Pneumonia, Invasive pneumococcal disease, Group A Streptococcus disease
Drug pages
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Next 30 days
- Nov 8in 14 daysPBGENE-HBV · Phase 1 results (ELIMINATE-B) · Chronic Hepatitis B
Next 60 days
- Nov 28in 34 daysD-PLEX 100 · FDA decision · Surgical site infection prevention · colorectal surgery
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in October 2026
- October 2026VYD2311 · Phase 3 topline results (DECLARATION) · COVID-19 prevention · adults and adolescents with and without risk factors
Expected by end of 2026
- By year-end 2026ABI-6250 · Phase 2 start · Chronic hepatitis delta virus
Expected in Q1 2027
- Q1 2027TNX-4800 · Phase 2 start · Lyme disease prevention
Expected in H1 2027
- H1 2027VAX-24 / VAX-31 · Phase 3 start · Invasive pneumococcal disease · infants
- H1 2027VAX-31 · Phase 3 results (OPUS-2, OPUS-3) · Invasive pneumococcal disease · adults
Expected by end of June 2027
- mid-2027TNX-801 · Phase 1 start · Smallpox and mpox prevention